Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Familial juvenile hyperuricemia in early childhood in a boy with a novel gene mutation.

CEN case reports

Takemasa Y, Hirano D, Kawakami Y, Tokunaga A, Umeda C, Miwa S, Kakegawa D, Ito A, Ida H.
PMID: 33616882
CEN Case Rep. 2021 Aug;10(3):426-430. doi: 10.1007/s13730-020-00566-7. Epub 2021 Feb 22.

Familial juvenile hyperuricemic nephropathy (FJHN) is a rare autosomal dominant disease caused by mutations in the uromodulin (UMOD) gene. It is characterized by the development of gout, tubulointerstitial nephropathy, and end-stage renal disease. Here we report a case of...

Cite
Takemasa Y, Hirano D, Kawakami Y, et al. Familial juvenile hyperuricemia in early childhood in a boy with a novel gene mutation. CEN Case Rep. 2021;10(3):426-430doi: 10.1007/s13730-020-00566-7.
Takemasa, Y., Hirano, D., Kawakami, Y., Tokunaga, A., Umeda, C., Miwa, S., Kakegawa, D., Ito, A., & Ida, H. (2021). Familial juvenile hyperuricemia in early childhood in a boy with a novel gene mutation. CEN case reports, 10(3), 426-430. https://doi.org/10.1007/s13730-020-00566-7
Takemasa, Yoichi, et al. "Familial juvenile hyperuricemia in early childhood in a boy with a novel gene mutation." CEN case reports vol. 10,3 (2021): 426-430. doi: https://doi.org/10.1007/s13730-020-00566-7
Takemasa Y, Hirano D, Kawakami Y, Tokunaga A, Umeda C, Miwa S, Kakegawa D, Ito A, Ida H. Familial juvenile hyperuricemia in early childhood in a boy with a novel gene mutation. CEN Case Rep. 2021 Aug;10(3):426-430. doi: 10.1007/s13730-020-00566-7. Epub 2021 Feb 22. PMID: 33616882; PMCID: PMC8271040.
Copy Download .nbib Format: NLM
Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement.

Diabetes & metabolic syndrome

Valsaraj R, Singh AK, Gangopadhyay KK, Ghoshdastidar B, Goyal G, Batin M, Mukherjee D, Sengupta U, Chatterjee S, Sengupta N.
PMID: 31991299
Diabetes Metab Syndr. 2020 Mar - Apr;14(2):93-100. doi: 10.1016/j.dsx.2020.01.007. Epub 2020 Jan 17.

AIM: The definition and management of asymptomatic hyperuricemia has been an area of controversy for many decades. Debate persists regarding the benefit of treating all cases of asymptomatic hyperuricemia and hence, unsurprisingly there are no clear clinical practice guidelines...

Cite
Valsaraj R, Singh AK, Gangopadhyay KK, et al. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes Metab Syndr. 2020;14(2):93-100doi: 10.1016/j.dsx.2020.01.007.
Valsaraj, R., Singh, A. K., Gangopadhyay, K. K., Ghoshdastidar, B., Goyal, G., Batin, M., Mukherjee, D., Sengupta, U., Chatterjee, S., & Sengupta, N. (2020). Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes & metabolic syndrome, 14(2), 93-100. https://doi.org/10.1016/j.dsx.2020.01.007
Valsaraj, Rahul, et al. "Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement." Diabetes & metabolic syndrome vol. 14,2 (2020): 93-100. doi: https://doi.org/10.1016/j.dsx.2020.01.007
Valsaraj R, Singh AK, Gangopadhyay KK, Ghoshdastidar B, Goyal G, Batin M, Mukherjee D, Sengupta U, Chatterjee S, Sengupta N. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes Metab Syndr. 2020 Mar - Apr;14(2):93-100. doi: 10.1016/j.dsx.2020.01.007. Epub 2020 Jan 17. PMID: 31991299.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries